US food benefits for the poor to be reduced as pandemic provisions end

Published Date: 02 Mar 2023

As the federal government ends pre-approved benefits during the early stages of the COVID-19 pandemic, low-income Americans could receive less food assistance or lose their eligibility altogether.

Read Full News

Latest News

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Joshua Wechsler, MD, on dupilumab's sustained efficacy in pediatric patients with EoE Joshua Wechsler, MD, MSCI

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

NASPGHAN: Best Practices for Celiac Disease Follow-up with Dale Lee, MD Dale Lee, MD

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, Reacts to the FDA Approval of Linaclotide for Pediatric IBS-C Julie Khlevner, MD, AGAF

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Rimegepant Linked to Increased Rectal Compliance, Reduced Rectal Sensation in IBS, With Ayah Matar, MD Ayah Matar, MD

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

Todays Updates

Episode 159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines Marco Meglio, Benjamin Tolchin, MD, MS, FAAN

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

FDA Grants Orexin Agonist Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 Isabella Ciccone, MPH

Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.

Todays Updates

Episode 159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines Marco Meglio, Benjamin Tolchin, MD, MS, FAAN

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

FDA Grants Orexin Agonist Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 Isabella Ciccone, MPH

Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.

Latest News

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

News All Time

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

H. pylori Geographical Prevalence and NASPGHAN/ESPGHAN Guidelines, With Silvana Bonilla, MD Silvana Bonilla, MD

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

5 Gastroenterology Headlines You Missed in November 2025

5 Gastroenterology Headlines You Missed in November 2025

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

HCPLive 5 Stories in Under 5: Week of 10/05 Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

FDA Approves Updated Indication for Upadacitinib (Rinvoq) in IBD Abigail Brooks, MA

The decision updates the indication statements for ulcerative colitis and Crohn’s disease to allow use in patients who have received ≥ 1 approved systemic therapy.

Empirical Donor Selection, 2-Dose Capsule FMT Regimen Improve C Diff Cure Rates Abigail Brooks, MA

Findings from the quality improvement study provide real-world data supporting empirical donor exclusion and multiple-dose capsule FMT to increase CDI cure rates.

Conference Preview: American College of Gastroenterology’s 2025 Annual Scientific Meeting Abigail Brooks, MA

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

ACP Releases Position Paper on Colorectal Cancer Screening, Surveillance Abigail Brooks, MA

The ACP Performance Measurement Committee reviewed 5 performance measures for CRC screening, ultimately only supporting 1 of them.

Recommended News For You

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

Discovery of a new biomarker for early detection of bladder cancer in both dogs and humans

C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.

After three years, responses to mounetuzumab in follicular lymphoma are still stable.

Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?

Psychiatric Disorders Are Common in Dementia Patients.

An understudied type of breast cancer poses a lurking threat

Recommended Articles For You

Innovative Strategies in Prostate Cancer Management: From Surveillance to Systemic Therapies 

Gene Therapy for Hemophilia: A New Hope on the Horizon 

Understanding Extramammary Paget's Disease: Causes, Symptoms and Treatment Options 

The Genetics of Bernard Soulier Syndrome: What We Know so Far 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Unlocking the potential of targeted therapies for multiple myeloma

2.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

3.

Study finds common genetic target may halt breast cancer cell growth

4.

Medical Journal March 29, 2023

5.

The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.

1.

New Frontiers in Diagnosing and Managing Myelodysplastic Syndromes (MASLD)

2.

Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment

3.

The Surprising Role of Magnesium in Digestion, Sleep and Mental Health 

4.

Engineering the Future of Oncology with CAR- Natural Killer Cell Design & Therapeutics

5.

Radiation Oncology Advances: Guidelines, Trials, Digital Tools & Education

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

3.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

4.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

5.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot